Novo Nordisk expands Wegovy $499-per-month offering

Novo Nordisk (NVO) announced updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month. Until today, the $499-per-month offer for Wegovy was only available via the recently launched NovoCare Pharmacy. “At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them accessible to and affordable for the communities we serve,” said Dave Moore, Executive Vice President, U.S. Operations and Global Business Development and President of Novo Nordisk Inc. “With the evolution of our Wegovy savings program, we continue to deliver options that empower people living with obesity to more easily pursue their weight management and health goals.”